JP2022509257A5 - - Google Patents
Info
- Publication number
- JP2022509257A5 JP2022509257A5 JP2021530883A JP2021530883A JP2022509257A5 JP 2022509257 A5 JP2022509257 A5 JP 2022509257A5 JP 2021530883 A JP2021530883 A JP 2021530883A JP 2021530883 A JP2021530883 A JP 2021530883A JP 2022509257 A5 JP2022509257 A5 JP 2022509257A5
- Authority
- JP
- Japan
- Prior art keywords
- leukemia
- combination according
- composition according
- compound
- venetoclax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773686P | 2018-11-30 | 2018-11-30 | |
| US62/773,686 | 2018-11-30 | ||
| PCT/US2019/063993 WO2020113216A1 (en) | 2018-11-30 | 2019-12-02 | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509257A JP2022509257A (ja) | 2022-01-20 |
| JP2022509257A5 true JP2022509257A5 (enExample) | 2022-12-14 |
Family
ID=70849819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530883A Pending JP2022509257A (ja) | 2018-11-30 | 2019-12-02 | ２，３－ジヒドロ－イソインドール－１－オン化合物を用いた組合せ療法及び様々な変異を有する患者を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200171001A1 (enExample) |
| EP (1) | EP3886840A4 (enExample) |
| JP (1) | JP2022509257A (enExample) |
| KR (1) | KR20210150353A (enExample) |
| CN (1) | CN113365622A (enExample) |
| AU (1) | AU2019387508A1 (enExample) |
| CA (1) | CA3133376A1 (enExample) |
| WO (1) | WO2020113216A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY39137A (es) * | 2020-04-01 | 2021-10-29 | Fmc Corp | Atropisómeros de derivados de piridazinona como herbicidas |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| DK2940014T3 (en) * | 2012-12-28 | 2018-12-10 | Crystalgenomics Inc | 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
| US20160312311A1 (en) * | 2013-03-12 | 2016-10-27 | Novartis Ag | Markers for isocitrate dehydrogenase inhibitors |
| US20160287592A1 (en) * | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
| AU2016304172A1 (en) * | 2015-08-03 | 2018-03-15 | Gilead Sciences, Inc. | Combination therapies for treating cancers |
| MA43374A (fr) * | 2015-12-04 | 2018-10-10 | Agios Pharmaceuticals Inc | Méthodes de traitement de tumeurs malignes |
| MX2018008169A (es) * | 2015-12-30 | 2019-02-20 | Agios Pharmaceuticals Inc | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. |
| CN109789127B (zh) * | 2016-07-29 | 2022-03-25 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
| WO2018081830A1 (en) * | 2016-10-31 | 2018-05-03 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
| KR20190128646A (ko) * | 2017-02-21 | 2019-11-18 | 압토스 바이오사이언시스 인코포레이티드 | 혈액 종양 환자들의 치료 방법 |
-
2019
- 2019-12-02 US US16/700,426 patent/US20200171001A1/en not_active Abandoned
- 2019-12-02 CN CN201980090539.1A patent/CN113365622A/zh active Pending
- 2019-12-02 KR KR1020217019708A patent/KR20210150353A/ko not_active Ceased
- 2019-12-02 JP JP2021530883A patent/JP2022509257A/ja active Pending
- 2019-12-02 AU AU2019387508A patent/AU2019387508A1/en not_active Abandoned
- 2019-12-02 CA CA3133376A patent/CA3133376A1/en active Pending
- 2019-12-02 EP EP19888779.6A patent/EP3886840A4/en not_active Withdrawn
- 2019-12-02 WO PCT/US2019/063993 patent/WO2020113216A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lü et al. | Homoharringtonine and omacetaxine for myeloid hematological malignancies | |
| JP2024507938A5 (enExample) | ||
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| JP2011503063A5 (enExample) | ||
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| JP2020505433A5 (enExample) | ||
| JP2020535173A5 (enExample) | ||
| JP2020117553A5 (enExample) | ||
| JP2023508496A5 (enExample) | ||
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| CN113908159A (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| JP2020508313A5 (enExample) | ||
| JP2024542984A5 (enExample) | ||
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Wang et al. | Homoharringtonine: mechanisms, clinical applications and research progress | |
| Song et al. | Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase I study | |
| JP7489397B2 (ja) | Ｒ－ｃｈｏｐとの組み合わせ及び複合薬におけるチダミドの適用 | |
| JP2023505301A5 (enExample) | ||
| JP2021522246A5 (enExample) | ||
| JP2021522246A (ja) | 癌治療のための併用 | |
| JP2023548303A5 (enExample) | ||
| Sangwan et al. | Imatinib analogs in chronic myeloid leukemia: a systematic qualitative review | |
| WO2021160147A1 (zh) | 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途 | |
| Barber et al. | Hematologic toxicities of small molecule tyrosine kinase inhibitors |